Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASE1 | P07998 | 1/20 | 0.54 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.50 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.50 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.50 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.50 |
| ▸ | DUT | P33316 | 4/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | TK1 | P04183 | 1/20 | 0.41 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.40 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19813629 | 1.00 | RNASE1 (0.54) | RNASE1SLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL19813627 | 0.92 | RNASE1 (0.53) | RNASE1SLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL13626717 | 0.90 | RNASE1 (0.53) | RNASE1SLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL13626065 | 0.90 | RNASE1 (0.53) | RNASE1SLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL4339977 | 0.90 | RNASE1 (0.53) | RNASE1SLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL4339980 | 0.90 | RNASE1 (0.53) | RNASE1SLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL20883495 | 0.88 | RNASE1 (0.71) | RNASE1SLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL13901234 | 0.88 | RNASE1 (0.52) | RNASE1SLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL25397715 | 0.86 | SLC28A1 (0.52) | RNASE1SLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL22300663 | 0.86 | SLC28A1 (0.52) | RNASE1SLC28A1SLC28A2SLC29A1SLC28A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180030080-A1 | Phosphoramidate nucleoside prodrug for treating viral diseases and cancer, processes for their preparation and their use | IVACHTCHENKO ALEXANDRE VASILIEVICH (US) | 2018-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180030080-A1 | Phosphoramidate nucleoside prodrug for treating viral diseases and cancer, processes for their preparation and their use | HCCS, NTPCR, NSUN2 | RNASE1 31/4885SLC28A1 5/4885SLC28A2 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.